PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. & PLUCK Application Number 09/674,035 Filing Date TRANSMITTAL December 11, 2000 **FORM** First Named Inventor Jas C. Lang Art Unit 1642 Examiner Name Larry Ronald Helms (to be used for all correspondence after initial filing) Attorney Docket Number 22727/04078 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC 1 Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a **Proprietary Information** Provisional Application After Final Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer **Extension of Time Request** below): Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Return receipt postcard Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF ARRUSANT ATTORNEY OR AGENT

Firm Name	SIGNATURE OF AFFL	ICANT, ATTORNET, OR AG	
riiii Name	Calfee, Halter & Griswold, LLP		
Signature	Sean In one		
Printed name	Sean C. Myers-Payne		
Date	April 15, 2005	Reg. No. 42,920	0

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

net L. Norris

Typed or printed name

April 15, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to Inis collection or information is required by 37 CFK 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USP10 to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited on April 15, 2015 with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Customer Number

24024

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

For:	Detecting the Expression of the DESC1 Gene in Squamous Cell Carcinoma)	MAIL STOP AF
Filed:	December 11, 2000))	Attorney Docket No.: 22727/04078
Applic	eation No.: 09/674,035)	Examiner: Larry Ronald Helms
	Jas C. Lang)	Group Art Unit: 1642
In re A	application of:)	

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE AFTER FINAL

This paper is responsive to the Office Action mailed February 17, 2005, setting an initial due date of May 17, 2005. This paper is timely filed and no fee is required.

Pursuant to 37 C.F.R. § 1.116, Applicant proposes amending the application as follows:

Amendments to the Claims begin on page 2; and

Remarks begin on page 4.